Yamanashi Prefectural Kita Hospital, Yamanashi, Japan.
Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
CNS Drugs. 2020 Jun;34(6):579-598. doi: 10.1007/s40263-020-00713-9.
Poor adherence to oral antipsychotics is common in patients with schizophrenia; nonetheless, there has been no systematic review or meta-analysis on medication adherence measured by electronic adherence monitoring (EAM), considered by many as the 'gold standard' assessment.
We systematically searched MEDLINE and Embase to identify studies investigating adherence to oral antipsychotics using EAM in patients with schizophrenia spectrum disorder. There were no exclusion criteria. We looked at the methodology in each study and defined which type of adherence was used in the study. Data on medication adherence, definition of satisfactory adherence (i.e., the threshold set in terms of the percentage of times medication was taken as prescribed), and factors associated with adherence were extracted for the included studies. Further, data on the rates of medication adherence were quantitatively synthesized.
A total of 19 studies involving 2184 patients were included. EAM-measured medication adherence was classified into three outcome types: taking adherence, regimen adherence, and timing adherence. The meta-analysis yielded oral antipsychotic adherence rates (defined as a continuous variable) of 71.1% for taking adherence [from seven studies, n = 256, 95% confidence interval (CI) 58.0-84.1], 70.0% for regimen adherence (from five studies, n = 174, 95% CI = 63.6-76.4), and 64.9% for timing adherence (from four studies, n = 212, 95% CI 53.2-76.6), respectively. The proportions of patients with oral antipsychotic adherence, when defined as a dichotomous variable, ranged from 50 to 78.3% for the 70% threshold for satisfactory adherence, 29.8-75.7% for the 75% threshold, and 47.8-75.7% for the 80% threshold. Factors associated with poor medication adherence were greater symptom severity, more frequent dosing regimen, poorer insight, and more negative drug attitude.
Oral antipsychotic adherence rates in schizophrenia, defined as a continuous variable and measured by EAM, were in the range of 70%, lower than the 80% threshold used widely to define satisfactory adherence.
精神分裂症患者普遍存在口服抗精神病药物依从性差的问题;然而,目前还没有系统的综述或荟萃分析评估电子药物监测(EAM)所测量的药物依从性,EAM 被许多人认为是“金标准”评估方法。
我们系统地检索了 MEDLINE 和 Embase,以确定使用 EAM 评估精神分裂症谱系障碍患者口服抗精神病药物依从性的研究。没有排除标准。我们研究了每项研究的方法,并确定了研究中使用的哪种类型的依从性。我们提取了药物依从性、满意依从性的定义(即根据按时服药的百分比设定的阈值)以及与依从性相关的因素的数据,纳入了研究。此外,我们还对药物依从率的数据进行了定量综合。
共有 19 项研究纳入了 2184 名患者。EAM 测量的药物依从性分为三种结果类型:服药依从性、方案依从性和时间依从性。荟萃分析得出的口服抗精神病药物依从率(定义为连续变量)分别为:服药依从性 71.1%[来自 7 项研究,n=256,95%置信区间(CI)58.0-84.1]、方案依从性 70.0%(来自 5 项研究,n=174,95%CI=63.6-76.4)和时间依从性 64.9%(来自 4 项研究,n=212,95%CI=53.2-76.6)。当以二项变量定义时,口服抗精神病药物依从率的患者比例范围为:70%的满意度阈值为 50-78.3%、75%的满意度阈值为 29.8-75.7%、80%的满意度阈值为 47.8-75.7%。与药物依从性差相关的因素包括更严重的症状、更频繁的给药方案、较差的病识感和更消极的药物态度。
通过 EAM 测量的精神分裂症患者的口服抗精神病药物依从率,定义为连续变量,在 70%的范围内,低于广泛用于定义满意依从性的 80%阈值。